Despite the encouraging results obtained in CD19+ B-ALL patients treated with the T-cell engaging bispecific antibody blinatumomab that targets CD19, a significant percentage of patients relapsed with CD19 B-ALL after treatment [7]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.